Navigation Links
New approaches may prevent certain side effects in BRAF mutation-positive melanoma

SAN FRANCISCO Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

The studies, presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011, further elucidated the potential mechanism of action underlying this skin lesion side effect, which could further the development of next-generation drugs with improved safety and efficacy profiles for the treatment of BRAF mutation-positive melanoma, according to the researchers.

"Our data suggest that adding an epidermal growth factor receptor (EGFR) inhibitor may prevent skin lesions that sometimes appear during treatment with a first-generation BRAF inhibitor," said Gideon Bollag, Ph.D., senior vice president of research at Plexxikon in Berkley, Calif. "Perhaps more importantly, our data also suggest that our next-generation BRAF inhibitors (which we call 'paradox breakers') represent a novel, single-agent treatment that may avoid this side effect and may also extend treatment durability."

In a laboratory study, Bollag and colleagues used skin cells activated by oncogenes such as HRAS or by signaling through the EGFR receptor with a first-generation BRAF inhibitor. They observed that treatment led to upregulation of ligands for the family of HER receptors, consequent skin cell transformation and enhanced growth. In contrast, Plexxikon's novel "paradox breakers" did not induce this upregulation and, therefore, may prevent the skin lesion side effect observed for all first-generation BRAF inhibitors to date.

Bollag said he and his research team were initially surprised by the upregulation of growth factor expression but were able to identify its cause with a model system. They then used this model system to differentiate the new "paradox breaker" compounds.

The "paradox breakers," which are in preclinical development, are being studied in BRAF-mutant cancer, and Plexxikon is aiming to file an investigational new drug application in 2012.


Contact: Jeremy Moore
American Association for Cancer Research

Related biology news :

1. LIAI launches new division to look at novel approaches to heart disease and inflammation
2. Genetic risk factors may tailor prostate cancer screening approaches
3. Experts discuss challenges in integrative approaches to science
4. MSU project may lead to new approaches against lung cancer
5. Swimming upstream: Molecular approaches to better understand male infertility
6. New paper examines approaches to measuring protein in foods in context of deadly adulterations
7. New approaches to skin cancer prevention
8. 2 in 1: Multi-tasking protein provides new approaches for anti-tuberculosis drugs
9. Project aims to fuse top-down, bottom-up approaches in systems biology
10. BUSM study identifies new potential approaches to treat myelofibrosis
11. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
Post Your Comments:
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
(Date:10/27/2015)... BERLIN, Germany , October 27, 2015 ... 2015. SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically ... SMI,s Eye Tracking Glasses , so that ... Suite BeGaze. --> Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 /PRNewswire/ ... innovator in modern authentication and a founding member of ... of its latest version of the Nok Nok™ S3 ... use standards-based authentication that supports existing and emerging methods ... is ideal for organizations deploying customer-facing applications that require ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology: